Ferrer Internacional

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents specifically designed to combat multidrug-resistant (MDR) Gram-negative infections. Founded in 2014, the company employs its innovative drug discovery platform, PasNas, to identify pathogen-specific antibacterial properties of various molecules. This platform not only promotes compounds effective against MDR strains but also emphasizes the importance of incorporating favorable pharmacokinetic and toxicological characteristics early in the development process. By focusing on first-in-class drugs and leveraging new mechanisms of action, ABAC Therapeutics aims to provide scalable and effective therapeutic alternatives for patients afflicted by antibiotic-resistant bacterial pathogens, addressing a critical need in modern medicine. As of November 2019, ABAC Therapeutics operates as a subsidiary of Tibidabo Ventures.

Alexza Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on the Staccato system, a hand-held inhaler designed to deliver drugs via inhalation, providing rapid systemic delivery.

Venter Pharma SL is a biotechnology company based in Alcobendas, Spain, dedicated to developing diagnostic drugs for lactose intolerance and other digestive disorders. Founded in 2003, the company emerged from research conducted by PhD Juan José Aragón Reyes and Alfonso Fernández Mayoralas at the Autonomous University of Madrid and the Spanish National Research Council. Venter Pharma focuses on creating innovative solutions that simplify and enhance clinical diagnosis, particularly in gastroenterology. Its flagship product, LacTEST, is designed to assist healthcare professionals in diagnosing lactose intolerance using a novel active substance called Gaxilose. By addressing common digestive pathologies, Venter Pharma aims to improve patient outcomes and facilitate more effective treatments for conditions with high prevalence, such as lactose intolerance and inflammatory diseases.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.